Content
Search
Navigation
Sitemap
About us
Pipeline & science
Overview
Obesity
Type 2 Diabetes Mellitus (T2DM)
Acute Ischemic Stroke (AIS)
Hypertension
Our expertise
Overview
Our strategic partners
Global opportunities
Join us
Press releases
Contact
简体中文
Search
简体中文
Navigation
Press releases
23 Mar 2026
Corxel Pharmaceuticals Enters into Asset Purchase Agreement with Everest Medicines for the Development and Commercialization of CARDAMYST™ (Etripamil) Nasal Spray in Greater China by Everest Medicines
Read article
22 Jan 2026
CORXEL Announces $287 million Series D1 Financing to Further Advance Its Cardiometabolic Pipeline including Oral Small Molecule GLP-1 Receptor Agonist
Read article
12 Dec 2025
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
Read article
13 Nov 2025
CORXEL Receives Study May Proceed Letter from the U.S. FDA for the Phase 2 Trial of CX11 in Patients with Type 2 Diabetes Mellitus
Read article
21 Jun 2025
Data from the Phase 2 Clinical Trial of CX11/VCT220 in China Presented at ADA 2025
Read article
17 Jun 2025
CORXEL Announces First Patient Enrolled in the U.S. Phase 2 Trial of CX11 in Obese and Overweight Patients
Read article
16 May 2025
CORXEL Announces First Patient Enrolled in ORION, the Registrational Clinical Trial of JX10 in Patients with Acute Ischemic Stroke
Read article
Load more
